Overview

Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors

Status:
Unknown status

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the gastrointestinal tolerability of EC-MPS compared to MMF in maintenance transplant patients on a calcineurin inhibitor regimen, who require MMF dose reductions of 25% or more due to GI complications. The tested hypothesis is that the EC-MPS treatment is superior to the MMF therapy in terms of tolerability and that patients on the EC-MPS formulation will be able to tolerate higher doses compared to those on MMF.

Phase:

Phase 4

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Calcineurin Inhibitors
Mycophenolate mofetil
Mycophenolic Acid